47. The estrogen receptor modulator compound for use in the treatment of an ER-related disease or condition according to claim 37 wherein the sample comprises nucleic acid from one or more tumor cells.

48. The estrogen receptor modulator compound for use in the treatment of an ER-related disease or condition according to claim 47 wherein the tumor cell is taken from a tumor biopsy sample, a blood sample, a serum sample, a lymph sample, or a bone marrow aspirate.

49. The estrogen receptor modulator compound for use in the treatment of an ER-related disease or condition according to claim 48 wherein the tumor cell is a circulating tumor cell.

50. The estrogen receptor modulator compound for use in the treatment of an ER-related disease or condition according to claim 49 wherein the sample comprises circulating tumor DNA (ctDNA).

51. A kit comprising one or more reagents for the detection of a mutation in *ESR1* and an estrogen receptor modulator compound of Formula (A), (B), (C), or (D) according to claim 1.

52. A pharmaceutical composition comprising an estrogen receptor modulator compound for use in the treatment of an ER-related disease or condition according to any of claims 1 to 50 and one or more pharmaceutically acceptable excipients.

53. The use of an estrogen receptor modulator compound according to any of claims 1 to 50 for the preparation of medicaments for use in the treatment of an ER-related disease or condition.

54. The use of an estrogen receptor modulator compound according to any of claims 1 to 50 for the treatment of an ER-related disease or condition.

55. A method for treating an ER-related disease or condition in a patient comprising administering an estrogen receptor modulator compound according to any of claims 1 to 34 to a patient.

~~56. The invention as described hereinbefore.~~

***